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to Republic Ministry of health of Serbia. In next regulatory step, after 
getting demand of Ministry of health of Serbia, ALIMS experts have 
to re-evaluate all registration documentation and their own decision 
in order to issue final decision.
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Introduction: BRINAVESS® /vernakalant/ is an antiarrhythmic med-
icine that acts preferentially in the atria to prolong atrial refractori-
ness and to rate dependently slow impulse. Anatomical Therapeutic 
Chemical Classification/ATC/ is: C01BG11.
Patients (or Materials) and Methods: According to Serbian Law 
on Medicinal Products and Medical Devices, regulatory procedural 
steps taken for getting Marketing Authorisation Approval in Serbia, 
started on 2011 year.
Results: After evaluation and reevaluation of submitted documenta-
tion/Module 1-5 Common Technical Document/, Advising Working 
Group for medicinal products of Medicines and Medical Devices 
Agency of Serbia suggested refusal application. On June 2012.year 
ALIMS issued the final decision/No. 515-01-0020-11-003/ about 
refusal registration. The reasons are related to divergence of facts 
cited in Summary Product Characteristics and pre-registration clini-
cal trials’ results devoted to efficacy, safety, statistical significance 
of total number of patients included in clinical phase of drug devel-
opment, as well as suspicion about the drug quality. Although the 
applicant declared that specified impurity limits in active substance 
are in accordance with preclinical toxicological testing, these results 
did not existed in Drug Master File, so the ALIMS assessor concluded 
that this applicant’s statement is not true.
Conclusion: Impossibility to submit requested additional revelant 
regulatory data caused applicant’s claim on March 2013.year for 
withdrawing registration of BRINAVESS® in Serbia.
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Introduction: Study of ethical aspects of relationships of pharma-
cists and patients during rendering of pharmaceutical services for 
the purpose of improving effectivness and safety of pharmacotherapy 
of patients.
Patients (or Materials) and Methods: A social poll using a method 
of selective anonymous survey of pharmacists and customers. The 
objects of research were the chemist’s shops of the city of Bishkek 
determined randomly. The analysis is based on the survey of 121 
pharmacists and 207 patients. The pharmacists were 45 (37.2%) 
specialists with university education and 76 (62.8%) with college 
education, the average age was 31.4 and the work of experience in 
pharmacy was 7.2 years. The patients were respondents older 18 
years old. The age distribution was 28.8% for 18–27; 34.6% for 
28–37; 9.7% for 38–47; 22.7% for 48 –57 and 4.2% for older 60. 
In terms of gender, the customers broke down into 133 (64.3%) 
female and 76 (35.7%) male. 45.3% of them had a university edu-
cation, 32.7% had a college education, and 21,9% were students. 
The received data were processed with the help of specialized SPSS 
statistical software package.
Results: According to the processed data most pharmacists (72,7%) 
know about the Code of Ethics for pharmacy practice and its con-
tents. All specialists (100%) admit that customers have the right to 
receive the information about the medicine they buy. As pharmacists 
note (64.5%), customers are most often interested in dosage and 
proper use of medicines. 63.6% of patients need professional assis-
tance when they choose a medicine. However, 27.1% of patients 
say pharmacists give consultations reluctantly. In the course of the 
research, customers of the chemist’s shops were suggested to evaluate 
some indices reflecting the degree of their satisfaction by pharmacists’ 
work (10-point scale). The average evaluation of the indices, such 
as appearance, consideration, tactfulness, patience and the ability 
to turn medical notions into plain language was 7.5. According to 
23.4% of pharmacists the most often reason of conflicts in chemist’s 
shops is patients’ dissatisfaction with a price of a medicine. This is 
confirmed by 67.7% patients thinking that most pharmacists are 
oriented for selling expensive and advertised medicines regardless 
of other affordable generics which do not concede in quality and 
effectiveness.
Conclusion: The research has revealed significant gaps in profes-
sional ethics of pharmacists. This allows us to make a conclusion that 
measures of interference in relationships of pharmacists and patients 
in the process of rendering pharmaceutical services need to be taken.
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Introduction: CXCL10 is a potent mast cell chemoattractant respon-
sible for the mast cell myositis characteristic of asthma. We have 
identified human airway smooth muscle (HASM) as a rich source 
of CXCL10 which is increased by TNF-alpha and IFN-gamma. We 
have previously shown that beta-agonists inhibit TNF-alpha induced 
CXCL10 release but the effect is lost when IFN-gamma is given 
concomitantly through poorly defined mechanisms. Here we defined 
the mechanism involved.
Patients (or Materials) and Methods: HASM cells taken from 3 nor-
mal donors were cultured using standard techniques. ELISA was 
used for quantitative measurement of CXCL10 release. Cyclic AMP 
assay was used to measure the cAMP level. Western Blot was used 
to indicate CREB phosphorylation.
Results: We found that salmeterol time dependently increased cAMP 
generation. TNF-alpha or IFN-gamma alone or in combination had 
similar effects on salmeterol time dependently induced cAMP genera-
tion suggesting that the inhibitory effect of IFN-gamma on beta-2 
agonist signaling was not at the level of cAMP generation but rather 
was likely to be an effect on downstream signaling pathways. Next 
we looked at the phosphorylation of CREB by Western blot and 
found that salmeterol and caused phosphorylation of CREB but this 
was differentially affected by the cytokines. Whereas TNF-alpha 
